• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 5. An alumina stabilized graphene oxide wrapped SnO2 hollow sphere LIB anode with improved lithium storage?
  Xiang Liu,Qian Sun,A. B. Djuri?i?,Maohai Xie,Baohu Dai,Jinyao Tang,Charles Surya,Changzhong Liao,Kaimin Shih RSC Adv., 2015,5, 100783-100789

Recent Advances in the Study of Tert-butyl 4-(6-chloropyrazin-2-ylamino)piperidine-1-carboxylate (CAS: 1147998-25-1)

Tert-butyl 4-(6-chloropyrazin-2-ylamino)piperidine-1-carboxylate (CAS: 1147998-25-1) is a key intermediate in the synthesis of various biologically active compounds, particularly in the development of kinase inhibitors. Recent studies have highlighted its significance in medicinal chemistry due to its versatile reactivity and potential applications in drug discovery. This research brief aims to summarize the latest findings related to this compound, focusing on its synthesis, biological activity, and potential therapeutic applications.

In a recent study published in the Journal of Medicinal Chemistry, researchers explored the synthetic pathways for Tert-butyl 4-(6-chloropyrazin-2-ylamino)piperidine-1-carboxylate, emphasizing its role as a precursor for novel kinase inhibitors. The study demonstrated that this compound can be efficiently synthesized through a multi-step process involving palladium-catalyzed cross-coupling reactions and subsequent functional group transformations. The optimized synthetic route achieved a high yield and purity, making it suitable for large-scale production.

Another significant advancement was reported in a 2023 paper in Bioorganic & Medicinal Chemistry Letters, where the compound was utilized as a building block for the development of selective JAK2 inhibitors. The researchers found that derivatives of Tert-butyl 4-(6-chloropyrazin-2-ylamino)piperidine-1-carboxylate exhibited potent inhibitory activity against JAK2, a kinase implicated in various hematologic malignancies. The study provided valuable insights into the structure-activity relationship (SAR) of these derivatives, paving the way for the design of more effective therapeutics.

Furthermore, a collaborative study between academic and industrial researchers investigated the pharmacokinetic properties of Tert-butyl 4-(6-chloropyrazin-2-ylamino)piperidine-1-carboxylate and its derivatives. The results, published in Drug Metabolism and Disposition, revealed favorable absorption and distribution profiles, suggesting their potential for oral administration. The study also identified key metabolic pathways, which could inform future drug development efforts to enhance stability and reduce toxicity.

In addition to its applications in kinase inhibitor development, Tert-butyl 4-(6-chloropyrazin-2-ylamino)piperidine-1-carboxylate has shown promise in other therapeutic areas. A recent preprint on bioRxiv described its use in the synthesis of novel antiviral agents targeting RNA viruses. The researchers reported that certain derivatives exhibited broad-spectrum activity against several pathogenic viruses, including SARS-CoV-2 and influenza. These findings underscore the compound's versatility and potential for addressing unmet medical needs.

Despite these promising developments, challenges remain in the optimization of Tert-butyl 4-(6-chloropyrazin-2-ylamino)piperidine-1-carboxylate-based therapeutics. Issues such as off-target effects, metabolic stability, and formulation compatibility need to be addressed in future studies. However, the compound's unique chemical properties and demonstrated biological activity make it a valuable candidate for further investigation.

In conclusion, recent research on Tert-butyl 4-(6-chloropyrazin-2-ylamino)piperidine-1-carboxylate (CAS: 1147998-25-1) has expanded our understanding of its synthetic utility and therapeutic potential. Its role as a key intermediate in the development of kinase inhibitors and antiviral agents highlights its importance in modern drug discovery. Continued exploration of its derivatives and optimization strategies will likely yield new breakthroughs in the treatment of various diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)